Tobramycin Sulfate | CAS#49842-07-1 | antibiotic

MedKoo Cat#: 561624 | Name: Tobramycin Sulfate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tobramycin is an effective antibiotic commonly used in the management and treatment of various systemic and ocular infections. As an aminoglycoside antibiotic, tobramycin is active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Tobramycin binds to the 16s ribosomal RNA component of the bacterial 30s ribosomal unit, inhibiting the initiation step of translation. By binding to the A-site, tobramycin induces mistranslation and causes transfer RNA to misread the codon, thus causing incorrect delivery of aminoacyl units. Incorrectly synthesized proteins build up inside the cell, disrupting the cell membrane and various cellular processes; this mechanism of action designates tobramycin as a bactericidal agent.

Chemical Structure

Tobramycin Sulfate

CAS#49842-07-1 (sulfate)

Theoretical Analysis

MedKoo Cat#: 561624

Name: Tobramycin Sulfate

CAS#: 49842-07-1 (sulfate)

Chemical Formula: C18H39N5O13S

Exact Mass:

Molecular Weight: 565.59

Elemental Analysis: C, 38.23; H, 6.95; N, 12.38; O, 36.77; S, 5.67

Price and Availability

Size	Price	Availability
250mg	USD 350.00	2 Weeks
1g	USD 550.00	2 Weeks
5g	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

32986-56-4 (free base) 79645-27-5 (sulfate deleted) 49842-07-1 (sulfate)

Synonym

Tobramycin Sulfate; Dartobcin; Nebcine; Tobraneg; Tobrasix;

IUPAC/Chemical Name

(2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol Sulfate

InChi Key

ZEUUPKVZFKBXPW-TWDWGCDDSA-N

InChi Code

InChI=1S/C18H37N5O9.H2O4S/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;1-5(2,3)4/h5-18,24-28H,1-4,19-23H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;/m0./s1

SMILES Code

O[C@H]1[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)C[C@H]3N)[C@@H](N)C[C@H]2N)O[C@H](CO)[C@@H](O)[C@@H]1N.O=S(O)(O)=O

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot# C23B08B18

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 565.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rosalia M, Chiesa E, Tottoli EM, Dorati R, Genta I, Conti B, Pisani S. Tobramycin Nanoantibiotics and Their Advantages: A Minireview. Int J Mol Sci. 2022 Nov 15;23(22):14080. doi: 10.3390/ijms232214080. PMID: 36430555; PMCID: PMC9692674. 2: Fiel SB, Roesch EA. The use of tobramycin for Pseudomonas aeruginosa: a review. Expert Rev Respir Med. 2022 May;16(5):503-509. doi: 10.1080/17476348.2022.2057951. Epub 2022 Apr 4. PMID: 35320051. 3: Schwarz C, Taccetti G, Burgel PR, Mulrennan S. Tobramycin safety and efficacy review article. Respir Med. 2022 Apr-May;195:106778. doi: 10.1016/j.rmed.2022.106778. Epub 2022 Feb 25. PMID: 35249787. 4: Elborn JS, Blasi F, Haworth CS, Ballmann M, Tiddens HAWM, Murris-Espin M, Chalmers JD, Cantin AM. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med. 2022 Feb;192:106728. doi: 10.1016/j.rmed.2021.106728. Epub 2022 Jan 1. PMID: 34998112. 5: Mah FS, Karpecki PM. Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis. Ophthalmol Ther. 2021 Dec;10(4):859-875. doi: 10.1007/s40123-021-00401-x. Epub 2021 Oct 27. PMID: 34708391; PMCID: PMC8589901. 6: Karki K, Sigdel S, Kafle S. Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis? Cureus. 2021 Aug 20;13(8):e17326. doi: 10.7759/cureus.17326. PMID: 34567873; PMCID: PMC8451513. 7: Le T, Lord L, Pignataro S, Simioni D, Cheah R. Evaluating the Impact of Education on Pharmacist Tobramycin Dose Recommendations for Cystic Fibrosis and a Review of Perceptions on Pharmacist-Led Charting. J Pharm Pract. 2022 Dec;35(6):903-910. doi: 10.1177/08971900211018419. Epub 2021 May 20. PMID: 34013814. 8: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Tobramycin. 2021 Feb 15. PMID: 30000174. 9: Alemu BM, Worku T. Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis. SAGE Open Med. 2020 Sep 18;8:2050312120958846. doi: 10.1177/2050312120958846. PMID: 32995001; PMCID: PMC7502802. 10: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Tobramycin. 2019 Apr 12. PMID: 31643824. 11: Hamed K, Debonnett L. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Ther Adv Respir Dis. 2017 May;11(5):193-209. doi: 10.1177/1753465817691239. Epub 2017 Feb 17. PMID: 28470103; PMCID: PMC5933546. 12: Vazquez-Espinosa E, Marcos C, Alonso T, Giron RM, Gomez-Punter RM, Garcia- Castillo E, Zamora E, Cisneros C, Garcia J, Valenzuela C, Ancochea J. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis. Expert Rev Anti Infect Ther. 2016;14(1):9-17. doi: 10.1586/14787210.2016.1118344. Epub 2015 Dec 4. PMID: 26559549. 13: Vázquez-Espinosa E, Girón RM, Gómez-Punter RM, García-Castillo E, Valenzuela C, Cisneros C, Zamora E, García-Pérez FJ, Ancochea J. Long-term safety and efficacy of tobramycin in the management of cystic fibrosis. Ther Clin Risk Manag. 2015 Mar 12;11:407-15. doi: 10.2147/TCRM.S75208. PMID: 25792839; PMCID: PMC4362982. 14: Somayaji R, Parkins MD. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis. Ther Deliv. 2015 Feb;6(2):121-37. doi: 10.4155/tde.14.94. PMID: 25690082. 15: Shteinberg M, Elborn JS. Use of inhaled tobramycin in cystic fibrosis. Adv Ther. 2015 Jan;32(1):1-9. doi: 10.1007/s12325-015-0179-3. Epub 2015 Jan 27. PMID: 25620537. 16: de Velde F, Emonts M, Verbruggen S, van der Sijs H. High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure. J Antimicrob Chemother. 2014 Nov;69(11):3163-4. doi: 10.1093/jac/dku260. Epub 2014 Jul 7. PMID: 25006239. 17: Lam J, Vaughan S, Parkins MD. Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis. Clin Med Insights Circ Respir Pulm Med. 2013 Nov 13;7:61-77. doi: 10.4137/CCRPM.S10592. PMID: 24324354; PMCID: PMC3836451. 18: Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K, Tappenden P. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. Eur Respir Rev. 2013 Dec;22(130):476-86. doi: 10.1183/09059180.00001513. PMID: 24293463; PMCID: PMC9639188. 19: Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model. Health Technol Assess. 2013 Dec;17(56):v-xvii, 1-181. doi: 10.3310/hta17560. PMID: 24290164; PMCID: PMC4781138. 20: McKeage K. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs. 2013 Nov;73(16):1815-27. doi: 10.1007/s40265-013-0141-0. PMID: 24194436.